#China #Shanghai #InventisBio #TYK2 Inhibitor #Nomelcitinib

InventisBio's Nomelcitinib Phase III Study: A Breakthrough in Psoriasis Treatment

In an exciting advancement for those suffering from moderate to severe plaque psoriasis, InventisBio Co., Ltd. has unveiled the results of its Phase III clinical trial focused on its novel TYK2 inhibitor, nomelcitinib (D-2570). This pivotal study not only met the primary endpoint but also confirmed the key secondary endpoint, showcasing substantial efficacy and a commendable safety profile when compared to the placebo group.

Study Highlights

The Phase III trial is a multicenter, double-blind, and placebo-controlled study, designed specifically to evaluate the effectiveness and safety of nomelcitinib in patients afflicted by plaque psoriasis. A total of 391 patients participated in the trial, assigned randomly in a 1:1:1 ratio to one of two treatment groups receiving nomelcitinib or a placebo.

The primary endpoint targeted a PASI (Psoriasis Area Severity Index) score improvement of at least 90% by week 16 (/PASI 90), while the secondary endpoint aimed for a Physician Global Assessment (PGA) score of 0 or 1, indicating a clear or nearly clear skin condition.

Results Overview

After 16 weeks, it was revealed that both doses of nomelcitinib yielded over 70% of patients achieving the PASI 90 response, showcasing significant superiority over the placebo group (p<0.0001). Furthermore, more than 80% of patients in the nomelcitinib group achieved the desired PGA score, again significantly higher than those in the placebo category (p<0.0001). This impressive outcome not only underscores the efficacy of nomelcitinib but also indicates rapid onset, with significant improvements noted as early as week 4.

The results resonate strongly with earlier Phase II findings, reaffirming nomelcitinib's efficacy in psoriasis treatment.

Safety Profile

Over the course of the trial, nomelcitinib exhibited a favorable safety profile, aligning with earlier studies. No new safety concerns emerged, reassured by the consistent tolerability observed. InventisBio's Chief Medical Officer, Ling Zhang, expressed enthusiasm over these results, underscoring that they support their previous findings and emphasize the drug's potential.

Future Prospects

Further solidifying its stance in psoriasis treatment, InventisBio is concurrently running another head-to-head Phase III clinical trial, comparing nomelcitinib to the active control, deucravacitinib. This study aims to provide additional data on the effectiveness and safety of this innovative compound. Moreover, Phase II studies assessing nomelcitinib's efficacy for various other conditions, including ulcerative colitis and systemic lupus erythematosus, are also underway in the U.S. and China.

About Nomelcitinib and InventisBio

Nomelcitinib is an oral selective inhibitor that specifically targets the tyrosine kinase 2 (TYK2) pathway, designed for autoimmune disease management. By inhibiting TYK2 kinase activity, it effectively dampens the immune response associated with psoriasis.

As a trailblazer in the biopharmaceutical sector, InventisBio is dedicated to addressing pressing medical needs, particularly within oncology, metabolic disorders, and autoimmune diseases. With a commitment to innovative drug development, the company aims to deliver safer and more effective treatment options globally.

This Phase III trial marks a significant milestone in psoriasis treatment and adds momentum to the ongoing research and development endeavors of InventisBio. With the landscape of psoriasis therapy rapidly evolving, nomelcitinib's promising results could pave the way for new, effective treatment modalities that significantly enhance patients' lives.